Cynata Therapeutics Ltd has released a press release.
Cyanta & Celularity Inc Execute MOU
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Encouraging Early Data-Cynata Clinical Trial Proceeds
- Final Preclinical Asthma Study Confirms Efficacy
- United States Patent Allowance for Core Cynata Technology
- Enrolment Completed in 1st Cohort of Cynata Clinical Trial
- September 2017 Quarterly Report
Later from Cynata Therapeutics
- Cynata Treats First Patient in Cohort B
- December 2017 Quarterly Report
- Cynata Engineered MSC Study Review Reveals Promising Results
- Excellent Data from Final Preliminary Evaluation Period
- FDA Grants Orphan Drug Designation to Cyanta for CYP-001
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics